BioNexus Gene Lab Corp

BGLCReported to SECin USCIK 0001737523Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5
Form 4 lines at BioNexus Gene Lab Corp, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Tan Lee Su-LengChief Executive OfficerAward—338,709 sharesAug 14, 2026Tan Lee Su-LengChief Executive Officer—Award · Aug 14Award338,709Aug 14, 2026
Yap Chee Keong—Award—32,258 sharesAug 14, 2026Yap Chee Keong—Award · Aug 14Award32,258Aug 14, 2026
Bin Abdul Hamid Muhammad Azrul—Award—32,258 sharesAug 14, 2026Bin Abdul Hamid Muhammad Azrul—Award · Aug 14Award32,258Aug 14, 2026
Chong Set FuiChief Financial OfficerAward—96,774 sharesAug 14, 2026Chong Set FuiChief Financial Officer—Award · Aug 14Award96,774Aug 14, 2026
Low Jook Yuen—Award—16,129 sharesAug 14, 2026Low Jook Yuen—Award · Aug 14Award16,129Aug 14, 2026